Lilly diabetes drug helps patients shed average of 34 pounds, a development sure to boost sales
The Indianapolis-based drugmaker said it would complete submission of tirzepatide to the U.S. Food and Drug Administration in coming weeks for treatment of obesity and expects regulatory action as early as late 2023.